Cargando…
Function and therapeutic advances of chemokine and its receptor in nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of hepatic pathology, ranging from simple accumulation of fat in its most benign form, steatohepatitis, to cirrhosis in its most advanced form. The prevalence of NAFLD is 20–30% in adults, and 10–20% of patients with NAFLD progress to no...
Autores principales: | Chen, Wei, Zhang, Jing, Fan, Hui-Ning, Zhu, Jin-Shui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295708/ https://www.ncbi.nlm.nih.gov/pubmed/30574191 http://dx.doi.org/10.1177/1756284818815184 |
Ejemplares similares
-
Roles of Chemokines and Chemokine Receptors in Obesity-Associated Insulin Resistance and Nonalcoholic Fatty Liver Disease
por: Xu, Liang, et al.
Publicado: (2015) -
Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
por: Sotiropoulou, Maria, et al.
Publicado: (2021) -
Chemokine-Like Receptor 1 Deficiency Does Not Affect the Development of Insulin Resistance and Nonalcoholic Fatty Liver Disease in Mice
por: Gruben, Nanda, et al.
Publicado: (2014) -
Nuclear Receptors in Nonalcoholic Fatty Liver Disease
por: López-Velázquez, Jorge A., et al.
Publicado: (2012) -
Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease
por: Jin, Lihua, et al.
Publicado: (2015)